Aspen expects Mounjaro Africa sales above $124 million in current year
Aspen Pharmacare expects African sales of Eli Lilly’s Mounjaro to exceed 2 billion rand (about $124 million) in its current financial year, citing strong South Africa demand and planned launches in Nigeria and Kenya.
Aspen Pharmacare JSE:APN said it expects African sales of Eli Lilly's NYSE:LLY Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, supported by strong demand in South Africa and planned launches in Nigeria and Kenya. The company described Mounjaro as a blockbuster weight-loss and diabetes drug.